Trial register facet
Trial records reported in 2024 — page 2
51 records with a recorded report or completion year of 2024.
Showing 0 records on this page
Records
51 documents · page 2 of 3
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| STEP-HFpEF-DM-BODY-COMPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 731 | 2024 | Moderate |
| SUMMIT-ADHERENCEprogramme record | Tirzepatide | Phase 3 | Reported | Observational | — | 2024 | Very low |
| SUMMIT-BIOMARKERprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2024 | Very low |
| SUMMIT-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-4 | Tirzepatide | Phase 3 | Reported | Randomised withdrawal | 670 | 2024 | High |
| SURMOUNT-4-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2024 | Very low |
| SURMOUNT-4-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURMOUNT-4-REGIONAL-CNprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-OSA-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | High |
| SURMOUNT-OSA-1-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-OSA-1-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2024 | Very low |
| SURMOUNT-OSA-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | High |
| SURMOUNT-OSA-2-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURVO-PH2-MASH | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 295 | 2024 | Low |
| SURVO-PH2-MASH-PKprogramme record | Survodutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURVO-PH2-MASH-RENAL-IMPprogramme record | Survodutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURVO-PH2-OBESITY | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 387 | 2024 | Moderate |
| SURVO-PH2-OBESITY-ADHERENCEprogramme record | Survodutide | Phase 2 | Reported | Observational | — | 2024 | Very low |
| SURVO-PH2-OBESITY-ELDERLYprogramme record | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURVO-PH2-OBESITY-OLEprogramme record | Survodutide | Phase 2 | Reported | Single-arm open-label | — | 2024 | Very low |
| SYNERGY-NASH | Tirzepatide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 190 | 2024 | Low |
page 2 of 3